Phosphodiesterase type 5 inhibitors and kidney disease

Baris Afsar, Alberto Ortiz, Adrian Covic, Abduzhappar Gaipov, Tarik Esen, David Goldsmith, Mehmet Kanbay

Research output: Contribution to journalReview article

16 Citations (Scopus)

Abstract

Chronic kidney disease (CKD) represents a worldwide health problem. Traditionally, the nephroprotective treatment for CKD aims to slow progression to end-stage renal disease and includes dietary protein restriction, correction of metabolic acidosis, and renin–angiotensin system blockers. However, current standard therapeutic options may not be enough for preventing CKD progression in a subset of patients making necessary to develop novel therapeutic options to further slow renal function loss. Phosphodiesterase type 5 (PDE5) inhibitors represent a class of drugs traditionally used to treat erectile dysfunction and pulmonary hypertension. However, recent evidence suggests that PDE5 inhibitors may have additional therapeutic effects, such as cardioprotection and cerebrovascular protection. In the current review, we summarize PDE5 inhibitors’ utility in disease states and clinical conditions related to kidney disease such as systemic hypertension and acute and chronic kidney injury and discuss the mechanisms explaining possible kidney protective roles of PDE5 inhibitors. A recently completed phase 2 trials demonstrated that the long-acting PDE5 inhibitor PF-00489791 decreased albuminuria in patients with overt diabetic nephropathy when added on top of renin–angiotensin system blockade.

Original languageEnglish
Pages (from-to)1521-1528
Number of pages8
JournalInternational Urology and Nephrology
Volume47
Issue number9
DOIs
Publication statusPublished - Sep 26 2015
Externally publishedYes

Keywords

  • Diabetic nephropathy
  • Hypertension
  • Kidney protection
  • Phosphodiesterase inhibitors

ASJC Scopus subject areas

  • Nephrology
  • Urology

Fingerprint Dive into the research topics of 'Phosphodiesterase type 5 inhibitors and kidney disease'. Together they form a unique fingerprint.

  • Cite this

    Afsar, B., Ortiz, A., Covic, A., Gaipov, A., Esen, T., Goldsmith, D., & Kanbay, M. (2015). Phosphodiesterase type 5 inhibitors and kidney disease. International Urology and Nephrology, 47(9), 1521-1528. https://doi.org/10.1007/s11255-015-1071-4